Evidence map›Paper›PMID 35377786›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2022

Massively parallel, computationally guided design of a proenzyme.

Brahm J Yachnin, Laura R Azouz, Ralph E White, Conceição A S A Minetti, David P Remeta, Victor M Tan, Justin M Drake, Sagar D Khare

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Cis-nonProline peptides: Genuine occurrences and their functional roles.Protein science : a publication of the Protein Society · 2025
    Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Brahm J YachninDepartment of Chemistry & Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854.ORCID 0000-0001-6812-6329
Laura R AzouzDepartment of Chemistry & Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854.ORCID 0000-0002-9423-6000
Ralph E WhiteDepartment of Pharmacology, University of Minnesota, Minneapolis, MN 55455.
Conceição A S A MinettiDepartment of Chemistry & Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854.ORCID 0000-0002-9682-2898
David P RemetaDepartment of Chemistry & Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854.
Victor M TanInstitute for Quantitative Biomedicine, Rutgers, The State University of New Jersey, Piscataway, NJ 08854.ORCID 0000-0001-5869-2773
Justin M DrakeDepartment of Pharmacology, University of Minnesota, Minneapolis, MN 55455.
Sagar D KhareDepartment of Chemistry & Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854.ORCID 0000-0002-2255-0543
Rutgers, The State University of New Jersey · USUniversity of Minnesota · US

Funding

User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI PAUL David ADAMS, Gregory L Hura · 2017 to 2026
$28.6M
Rutgers Biotechnology Training ProgramT32GM135141 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI ANN M. STOCK, Martin L Yarmush · 2020 to 2026
$3.5M
Principles for Designing Stimulus-Responsive EnzymesR01GM132565 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI KHARE, SAGAR D · 2019 to 2022
$1.8M
A Pixel Array Detector System for Small Angle X-ray ScatteringS10OD018483 · OD · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI CLASSEN, SCOTT · 2014 to 2014
$998k
Elucidating Synergy of Enzalutamide and Src Kinase Inhibitors in Castration-Resistant Prostate CancerF31CA261056 · NCI · UNIVERSITY OF MINNESOTA · PI WHITE, RALPH E · 2021 to 2022
$63k
CIHRHHS | NIH | National Institute of General Medical Sciences (NIGMS) T32GM135141NCI NIH HHS F31 CA261056NIGMS NIH HHS P30 GM124169NIGMS NIH HHS R01 GM132565NIGMS NIH HHS T32 GM135141NIH HHS S10 OD018483
6 · The paper itself

Abstract

Confining the activity of a designed protein to a specific microenvironment would have broad-ranging applications, such as enabling cell type-specific therapeutic action by enzymes while avoiding off-target effects. While many natural enzymes are synthesized as inactive zymogens that can be activated by proteolysis, it has been challenging to redesign any chosen enzyme to be similarly stimulus responsive. Here, we develop a massively parallel computational design, screening, and next-generation sequencing-based approach for proenzyme design. For a model system, we employ carboxypeptidase G2 (CPG2), a clinically approved enzyme that has applications in both the treatment of cancer and controlling drug toxicity. Detailed kinetic characterization of the most effectively designed variants shows that they are inhibited by ∼80% compared to the unmodified protein, and their activity is fully restored following incubation with site-specific proteases. Introducing disulfide bonds between the pro- and catalytic domains based on the design models increases the degree of inhibition to 98% but decreases the degree of restoration of activity by proteolysis. A selected disulfide-containing proenzyme exhibits significantly lower activity relative to the fully activated enzyme when evaluated in cell culture. Structural and thermodynamic characterization provides detailed insights into the prodomain binding and inhibition mechanisms. The described methodology is general and could enable the design of a variety of proproteins with precise spatial regulation.

Indexed as

Computer-Aided DesignDrug DesignEnzyme Precursorsgamma-Glutamyl HydrolaseProtein EngineeringCatalytic DomainHumansPC-3 CellsEnzyme Precursorsgamma-Glutamyl Hydrolasecarboxypeptidase G2proenzyme designprotein designRosettazymogens

Identifiers

PMID35377786
PMCPMC9169645
OpenAlexW4226042892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.